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During viral infection, proper regulation of immune responses is necessary to ensure
successful viral clearance with minimal host tissue damage. Proteasomes play a crucial
role in the generation of antigenic peptides for presentation on MHC class I molecules,
and thus activation of CD8 T cells, as well as activation of the NF-κB pathway. A
specialized type of proteasome called the immunoproteasome is constitutively expressed
in hematopoietic cells and induced in non-immune cells during viral infection by interferon
signaling. The immunoproteasome regulates CD8 T cell responses to many viral epitopes
during infection. Accumulating evidence suggests that the immunoproteasome may
also contribute to regulation of proinﬂammatory cytokine production, activation of the
NF-κB pathway, and management of oxidative stress. Many viruses have mechanisms
of interfering with immunoproteasome function, including prevention of transcriptional
upregulation of immunoproteasome components as well as direct interaction of viral
proteins with immunoproteasome subunits. A better understanding of the role of the
immunoproteasome in different cell types, tissues, and hosts has the potential to improve
vaccine design and facilitate the development of effective treatment strategies for viral
infections.
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INTRODUCTION
The host outcome of viral infection depends on the success-
ful balance of immune responses that contribute to control of
viral replication, but those responses may also mediate aspects
of host tissue damage that accompany infection. Antibodies,
cytokines, CD4 T cells, and CD8 T cells can all play impor-
tant roles in controlling viral replication and viral clearance from
the host. CD8 T cells kill infected target cells by two major
pathways: perforin/granzyme-mediated pathways and Fas–Fas lig-
and (FasL)-mediated pathways (Russell and Ley, 2002; Hoves
et al., 2010). CD8 T cells can also contribute to elimination of
infected cells through production of antiviral cytokines, such as
IFN-γ and TNF-α. A number of viruses are eliminated at least
partially through CD8 T cell-dependent mechanisms in mouse
models, including lymphocytic choriomeningitis virus (LCMV),
inﬂuenza virus, the mouse-speciﬁc orthopoxvirus ectromelia
virus, and murine gammaherpesvirus (MHV-68; Ehtisham et al.,
1993; Kägi et al., 1994; Walsh et al., 1994; Müllbacher et al., 1999).
However, CD8 T cells can also contribute to CNS, liver, and
cardiac pathology during infection with LCMV and coxsack-
ievirus B3 (Buchmeier et al., 1980; Henke et al., 1995; Lang et al.,
2008).
CD8 T cells recognize peptides bound to MHC class I
molecules. The generation of peptide-MHC class I complexes
involves many steps (Figure 1). Peptides that bind tightly to
MHC class I are 8–11 amino acids in length and have anchor
residues, which are generally in the C-terminus, but can be present
elsewhere in the peptide sequence (Falk et al., 1991). The vast
majority of these peptides are generated by proteasomes (Rock
et al., 1994), although extended versions of peptides produced by
the proteasome can be trimmed by aminopeptidases in the cytosol
(Stoltze et al., 2000) or endoplasmic reticulum (ER; Snyder et al.,
1994; Craiu et al., 1997a). Peptides are transported from the cyto-
plasm to the ER by an ER-resident heterodimeric protein called
transporter for antigen processing (TAP; Neefjes et al., 1993). TAP
is a subunit of the MHC class-I-loading complex, a ∼1 MDa com-
plex within the ER, that clusters the molecules involved in MHC
class I loading in order to increase the efﬁciency of the process.
Once a peptide is successfully bound, the MHC class I molecule is
released from the MHC class-I-loading complex and delivered to
the cell surface for presentation to CD8 T cells.
Activation of CD8 T cells depends on the proteasome for gen-
eration of antigenic peptides presented on MHC class I molecules
on the surface of either infected cells or antigen presenting cells
(APCs). The immunoproteasome is a specialized type of protea-
some with altered peptide cleavage properties that is constitutively
expressed in hematopoietic cells and induced in non-immune
cells under conditions of inﬂammation. Evidence suggests that
the immunoproteasome may play an important role during
viral infection through regulation of CD8 T cell responses and
proinﬂammatory cytokine production, activation of the NF-κB
pathway, and management of oxidative stress (Groettrup et al.,
2009; Ebstein et al., 2012; Basler et al., 2013b; Warnatsch et al.,
2013).
STANDARD PROTEASOMES AND IMMUNOPROTEASOMES
Proteasomes are large complexes responsible for the regulated
degradation of almost all cellular proteins, and as such proteasome
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FIGURE 1 | MHC class I antigen presentation pathway. Proteins with
ubiquitin tags (red spheres) are degraded by proteasomes and the resulting
peptides are transported into the endoplasmic reticulum (ER) byTAP. In the
ER, the peptide is loaded onto MHC class I molecules by many molecular
chaperones. The peptide-MHC class I complex is then transported to the
cell surface for presentation to CD8T cells.
activity is required for cell viability (Rock et al., 1994; Tanaka,
1995). Proteasomes also play a primary role in the generation of
antigenic peptides for presentation on MHC class I molecules, but
not on MHC class II (Rock et al., 1994; Groettrup et al., 1996c;
Craiu et al., 1997b). The 20S proteasome core is a barrel-shaped
complex that is composed of four stacked heptameric rings: two
outer alpha rings and two inner beta rings (Figure 2A; Groll
et al., 1997; Unno et al., 2002). The proteasome may be associ-
ated with activator caps, discussed below. The catalytic activity is
restricted to three of the beta subunits, β1 (also called Y in ver-
tebrates), β2 (Z), and β5 (X), that account for the caspase-like,
trypsin-like, and chymotrypsin-like activities of the proteasome,
respectively (DeMartino and Slaughter, 1999). The active sites of
each of these proteins face toward the lumen of the proteasome
cylinder, preventing unrestricted exposure of cytosolic proteins to
proteolysis.
Almost 25 years ago, twomore β-type proteasome subunits that
are homologous to β1 and β5 were identiﬁed: proteasome subunit
β1i (also known as PSMB9 and LMP2, low molecular weight pro-
tein 2) and proteasome subunit β5i (also known as PSMB8 and
LMP7; Glynne et al., 1991; Kelly et al., 1991; Ortiz-Navarrete et al.,
1991). These subunits are encoded by genes in the MHC class II
region and are induced by IFN-γ and TNF-α (Aki et al., 1994),
leading to the designation of these subunits as “immunosubunits”
and the complex they form as the “immunoproteasome” (Tanaka,
1994; Figure 2A). A third IFN-γ-inducible proteasome subunit,
FIGURE 2 | Immunoproteasome formation and the thymoproteasome.
(A)The catalytic core of the 20S proteasome is comprised of two outer α
rings and two inner β rings. IFN-γ exposure induces the synthesis of three β
“immunosubunits,” which are incorporated into newly formed
proteasomes in place of their constitutive counterparts to form the 20S
immunoproteasome. (B) In the thymus, a specialized type of proteasome is
expressed in cTECs. This proteasome contains the immunosubunits β1i
and β2i as well as a cTEC-speciﬁc proteasome subunit β5t.
this one outside of the MHC region, was subsequently identiﬁed:
proteasome subunit β2i (also known as PSMB10, LMP10, and
MECL-1, multicatalytic endopeptidase complex-like 1), which
is homologous to β2 (Groettrup et al., 1996a; Hisamatsu et al.,
1996; Nandi et al., 1996). Expression of the three immunosubunits
following IFN-γ stimulation is mediated by interferon (IFN) reg-
ulatory factor-1 (IRF-1; Chatterjee-Kishore et al., 1998; Foss and
Prydz, 1999; Brucet et al., 2004; Namiki et al., 2005). Type I IFNs
can also upregulate the immunoproteasome, although higher con-
centrations are needed to achieve the same upregulation induced
by IFN-γ (Shin et al., 2006; Freudenburg et al., 2013a,b).
An additional type of specialized proteasome, termed the thy-
moproteasome, was identiﬁed in cortical thymic epithelial cells
(cTECs). This proteasome contains the immunosubunits β1i and
β2i as well as a cTEC-speciﬁc proteasome subunit β5t (also known
as PSMB11; Figure 2B). Expression of β5t is essential for positive
selection of T cells, and expression of the homologous subunits β5
or β5i cannot compensate for deﬁciency in this specialized subunit
(Murata et al., 2007; Nitta et al., 2010; Xing et al., 2013).
IMMUNOPROTEASOME FORMATION AND TISSUE
EXPRESSION
Immunoproteasome assembly occurs in a cooperative man-
ner whereby the immunosubunits interact with one another
to favor the assembly of immunoproteasomes containing all
three immunosubunits. This occurs even in cells that coexpress
both standard and immunosubunits (Grifﬁn et al., 1998). The
immunosubunit β1i is incorporated more quickly than β1, and
incorporation of β2i depends on that of β1i (Groettrup et al., 1997;
Frontiers in Microbiology | Virology January 2015 | Volume 6 | Article 21 | 2
McCarthy andWeinberg Immunoproteasome and viral infection
De et al., 2003). Incorporation of β5i is required for the matura-
tion (removal of the propeptides) of β1i and β2i, which would
otherwise prevent their catalytic activity (Groettrup et al., 1997;
Grifﬁn et al., 1998). β5i is the only subunit that canbe incorporated
into immunoproteasomes independently of the other subunits,
allowing for the existence of “mixed”or intermediate proteasomes
that contain both β1i/β5i or β5i without other immunosubunits
(Grifﬁn et al., 1998; Kingsbury et al., 2000). Mixed proteasomes
are present in some human tissue types in the absence of stim-
ulation or inﬂammation, especially the liver and colon, but not
the heart. They are particularly abundant (50% or greater of the
proteasomes in cell lysates) in APCs, such as monocytes and both
immature and mature DCs (Guillaume et al., 2010).
The spleen has the highest level of baseline immunopro-
teasome expression and activity compared to other organs
(Noda et al., 2000; Ebstein et al., 2012). This makes sense given
that the immunoproteasome is abundantly expressed in cells
of hematopoietic origin, including professional APCs such as
macrophages and B cells, found in the spleen (Frisan et al., 2000;
Haorah et al., 2004). Malignant cell lines derived from B cells
or multiple myeloma express high levels of immunoproteasome
subunits (Frisan et al., 1998; Altun et al., 2005). There has been
some disagreement regarding the regulation of immunoprotea-
some expression in DCs. Initial reports suggested that immature
DCs constitutively express immunoproteasomes at equal levels to
that of the standard proteasome. Upon maturation, immuno-
subunit expression is dramatically upregulated and synthesis of
new proteasomes switches exclusively to immunoproteasomes
(Macagno et al., 1999). Later reports showed that immunoprotea-
some content is unchanged or even decreased in DCs following
maturation (Li et al., 2001; Macagno et al., 2001; Ossendorp
et al., 2005). The disagreements regarding immunoproteasome
expression in DCs may have been due to lack of immunosubunit-
speciﬁc antibodies at the time of those studies. A more recent
study demonstrated the presence of mostly immunoproteasomes
and mixed proteasomes (β1/β2/β5i and β1i/β2/β5i) in imma-
ture DCs that does not change after maturation (Guillaume et al.,
2010).
Constitutive expression of immunoproteasome subunits by
immune cells appears to be independent of external signaling
requirements, such as persistent stimulation by cytokines in vivo,
because immune cells maintain their immunoproteasome expres-
sion in vitro in the absence of cytokines or other external stimuli.
Rather, the high basal levels of immunoproteasome expression in
immune cells are likely due topermanent activationof intracellular
signaling pathways. One report demonstrated minor reductions
in β1i and β5i mRNA in thymus and spleen tissue of mice lacking
either type I or type II IFN receptors (Lee et al., 1999), but a second
study demonstrated that the spleens of IFN-γ-deﬁcient mice have
levels of immunoproteasome protein expression similar to that of
wild-typemice (Barton et al., 2002). In spleens of STAT1−/− mice,
however, mRNA and protein expression of immunoproteasome
subunits is markedly reduced (Lee et al., 1999; Barton et al., 2002),
suggesting that basal immunoproteasome expression does not
require IFN-γ signaling (and therefore phosphorylated STAT1),
but it is at least partially dependent on non-phosphorylated
STAT1. This is supported by evidence that non-phosphorylated
STAT1 and IRF1 forma complex that occupies the IFN-γ-activated
sequence (GAS) elements of the β1i promoter to support its con-
stitutive expression (Chatterjee-Kishore et al., 2000). There is still
some basal immunoproteasome expression in spleens and thymus
of STAT1−/− mice. This may reﬂect equal reduction of immuno-
proteasome subunits in all immune cell types present in these
tissues (i.e., STAT1 greatly enhances basal expression), or could
be due to complete absence of immunoproteasome expression in
some cell types andnot others (i.e., a cell-type-speciﬁc dependence
on STAT1 for basal expression).
While non-immune cells express standard proteasomes almost
exclusively, immunoproteasome expression canbe induced in such
cells following exposure to IFN-γ. As mentioned above, type
I IFNs can also upregulate the immunoproteasome, although
less efﬁciently than IFN-γ (Shin et al., 2006; Freudenburg et al.,
2013a,b). An initial report suggested that TNF-α could act syn-
ergistically with IFN-γ to upregulate β5i expression (Hallermalm
et al., 2001), implying that other proinﬂammatory cytokines may
be capable of regulating immunoproteasomeexpression. However,
in three murine cell lines of non-hematopoietic origin, only IFN-γ
was capable of upregulating immunoproteasome subunit expres-
sion, and there was no effect of IL-1, IL-4, IL-6, TNF-α, TGF-β,
IL-3, or GM-CSF treatment on immunoproteasome subunit pro-
tein levels (Barton et al., 2002). Therefore, it seems that IFN
signaling is required for immunoproteasome induction in non-
hematopoietic cells and that other proinﬂammatory cytokines
cannot regulate immunoproteasome expression. There are some
exceptions to reports that non-immune cells express exclusively
standard proteasomes. For instance, constitutive immunoprotea-
some expressionhas been reported in immune-privileged sites that
are highly unlikely to be subject to persistent cytokine stimulation,
such as the eye and brain (Singh et al., 2002; Piccinini et al., 2003;
Ferrington et al., 2008), suggesting a role for immunoproteasomes
in non-immune processes.
26S AND 20S PROTEASOMES
Proteasomes exist in many forms in cells, with different regula-
tory or activator cap complexes that associate with the 20S core
to control access to the proteolytic inner chamber (Baumeister
et al., 1998). The α rings serve as scaffolds for the β subunits
during proteasome assembly, but they also serve as binding sites
for regulatory and activator complexes. The 26S proteasome,
which is composed of a 20S core particle and one or two 19S
(also known as PA700) regulatory caps, degrades proteins in
an ATP- and largely polyubiquitin-dependent manner. The 19S
regulator complex recognizes and binds polyubiquitin moieties,
then unfolds and feeds substrate proteins into the 20S core for
degradation (Navon and Goldberg, 2001). Although 26S protea-
somes preferentially degrade ubiquitinated proteins, degradation
can occur without ubiquitination if the protein is ﬁrst denatured
(Benaroudj et al., 2001). The 26S proteasome is responsible for the
majority of normal protein turnover within cells. Because the α
subunits are unchanged between different types of proteasomes,
the 19S regulator complex can associate with 20S cores contain-
ing either standard or immunosubunits. This makes possible a
number of different proteasome and immunoproteasome combi-
nations: 20S alone, asymmetric 26S proteasomes (19S-20S), or 26S
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(19S-20S-19S), with each capable of having either the standard or
immunosubunits in the 20S core (Figure 3).
It was originally thought that cells have little to no free 20S
proteasome, and that the 20S complex is incapable of acting
independently of its regulators or activators (Rivett et al., 2001).
Without the 19S regulatory cap, the 20S proteasome does not have
the ability to recognize and unfold polyubiquitinated proteins.
The 20S core seems to exist in an autoinhibited state, where the
N-terminal tails of the α subunits at the openings on either end
of the complex prevent substrate access to the internal proteolytic
chamber (Groll et al., 2000). Binding of activator or regulatory
complexes to the 20S core displaces the N-terminal tails, opening
a channel into the lumen of the proteasome (Whitby et al., 2000;
Köhler et al., 2001). However, even in the absence of activating
agents [such as heating or low detergent concentrations (Coux
et al., 1996)], the 20S core is capable of degrading proteins at low,
albeit detectable and reproducible, rates. Degradation of proteins
by the 20S core probably involves partial or transient opening
of the inner channel and is not an active process (Osmulski and
Gaczynska, 2000, 2002; Köhler et al., 2001; Osmulski et al., 2009).
Indeed, the 26S proteasome and immunoproteasome hydrolyze
unstructured polypeptides at rates nearly 10-fold higher compared
to 20S proteasomes and immunoproteasomes (Benaroudj et al.,
2001; Cascio et al., 2001; Raule et al., 2014a). However, the free 20S
core is capable of binding to and degrading proteins in a process
that is both ATP- and ubiquitin-independent (Ciechanover, 1994;
Coux et al., 1996). Rather than recognizing ubiquitin moieties,
the 20S proteasome has a selective preference for degradation of
damaged or oxidized proteins, while the 26S proteasome does not
(Reinheckel et al., 1998; Davies, 2001; Pickering et al., 2010). Thus,
it appears that the majority of normal protein turnover occurs
through the 26S proteasome, while the 20S proteasome plays a
specialized role in degradation of damaged or oxidized proteins.
It has been suggested that oxidation may act as a marker for tar-
geting proteins to the MHC class I pathway (Teoh and Davies,
2004). This notion, termed the PrOxI (protein oxidation and
immunoproteasome) hypothesis, would represent a new mech-
anism of substrate generation by the proteasome and may act
in concert with other pathways (such as the DRiPs pathway dis-
cussed below) to efﬁciently generate peptides for MHC class I
presentation.
PROTEASOME PROCESSING OF PEPTIDES FOR MHC CLASS I
The changes in proteasome subunit composition from standard
to immunosubunits in response to IFN-γ stimulation alter the
proteolytic activity of the complex. Puriﬁed 20S and 26S immuno-
proteasomes from IFN-γ-treated cells substantially increase the
rate at which they cleave after hydrophobic and basic residues
(Driscoll et al., 1993; Gaczynska et al., 1993; Aki et al., 1994) and
decrease the rate of cleavage after acidic residues (Gaczynska et al.,
1996). As the vast majority of peptides presented on MHC class
I have hydrophobic or basic C-termini, the immunoproteasome
is thought to generate peptides better suited to binding to MHC
class I molecules compared to the constitutive proteasome and
thus be more efﬁcient at eliciting immune responses (Driscoll
et al., 1993; Früh et al., 1994). Using ovalbumin (OVA) as a protein
substrate, rates of degradation by 26S proteasomes and immuno-
proteasomes, or 20S proteasomes and immunoproteasomes, are
indistinguishable (Cascio et al., 2001). All produce peptides of
similar sizes ranging between 3 and 22 residues. 26S particles yield
peptides with a mean size of 7–8 residues, while the mean size
of products from 20S particles is slightly larger, at 8–9 residues
(Kisselev et al., 1999). The different β subunits therefore do not
affect rates of protein degradation or peptide size, but rather seem
FIGURE 3 | Possible combinations of 20S proteasome core with
proteasome activator complexes. The 19S (PA700) regulatory cap
can associate at one or both ends of the 20S proteasome core to
form an asymmetric 26S proteasome or a 26S proteasome,
respectively. The IFN-γ-induced 11S (PA28) regulatory complex can
bind at the free end of a 19S-20S complex to form a hybrid
proteasome, or it can associate with both ends of the 20S
immunoproteasome core.
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to affect the cleavage sites within a protein to generate peptides
with more hydrophobic C-termini.
It was uncertain whether proteasomes cleave proteins to the
exact length (8–10 residues) that would be directly loaded onto
MHC class I molecules, or whether they produce larger precur-
sors that are further cleaved by other peptidases. Some initial
experiments indicated that isolated 20S proteasomes could cleave
larger peptides to antigenic epitopes (Niedermann et al., 1995,
1999; Lucchiari-Hartz et al., 2000). However, these experiments
used short (less than 50 amino acid) precursors that are likely very
different from the ubiquitinated or damaged full-length protein
substrates that the proteasome would encounter under normal
conditions. 20S proteasomes also release a different spectrum of
products than do 26S proteasomes (Kisselev et al., 1999; Emmerich
et al., 2000). A number of studies have indicated that proteasomes
release N-extended versions of antigenic peptides, which are then
trimmed by aminopeptidases in the cytosol (Stoltze et al., 2000) or
ER (Snyder et al., 1994; Craiu et al., 1997a). Moreover, one of these
aminopeptidases, leucine aminopeptidase (LAP), is induced by
IFN-γ (Beninga et al., 1998). Following IFN-γ treatment, cytosolic
LAPactivity accounted for all trimmingof anN-terminal extended
version of the well-studied OVA-derived epitope SIINFEKL to the
correct length.
Although immunoproteasomes degrade proteins at the same
rate as standard proteasomes, immunoproteasomes generate
more antigenic peptides than standard proteasomes (Cascio et al.,
2001). Degradation of OVA by standard 26S proteasomes iso-
lated from muscle tissue produces SIINFEKL or an N-extended
version only 6–8% of the time. When 26S immunoprotea-
somes from the spleen are used, the percentage of peptides
containing SIINFEKL at the C-terminus increases to 11%. This
is not due to an increase in the amount of ﬁnal SIINFEKL
peptide generated, as standard proteasomes and immunoprotea-
somes release the same amount of SIINFEKL. Instead, 20S or
26S immunoproteasomes generate 2–4 times the amount of N-
extended versions of this peptide, which could be trimmed by
the cytosolic enzyme LAP, compared to their standard protea-
some counterparts. Therefore, it seems that the effect of IFN-γ
on antigenic peptide generation within cells is at least threefold:
changes from standard to immunosubunits in the 20S protea-
some core directly affect C-terminal processing and generate
more N-extended versions of antigenic peptides, while induc-
tion of aminopeptidase activity in the cytosol alters N-terminal
processing.
IFN-γ-INDUCED PROTEASOME REGULATOR PA28
Another protein complex induced by IFN-γ is PA28 (also known
as REG or 11S), a large regulatory complex that binds the ends of
the 20S proteasome in an ATP-independent manner (Figure 3).
In mammals, PA28 is made of two homologous subunits, PA28α
(REGα or PSME1) and PA28β (REGβ or PSME2; Honoré et al.,
1993; Realini et al., 1994; Ahn et al., 1995, 1996; Jiang and Monaco,
1997; Tanahashi et al., 1997; Rechsteiner et al., 2000). A third PA28
family member, PA28γ (also known as REGγ or Ki antigen), is
structurally related to PA28α and PA28β. PA28γ associates with
20S proteasomes primarily in the nucleus, and unlike PA28α/β, it
is not induced by IFN-γ (Tanahashi et al., 1997). PA28γ does not
appear to play a role in the immune response, but is involved in reg-
ulation of cell proliferation and tumorigenesis through multiple
pathways (He et al., 2012; Ali et al., 2013; Li et al., 2013; Levy-
Barda et al., 2014). It was originally predicted that PA28α/β either
enhanced the rate of protein degradation by proteasomes or gen-
erated peptides better suited to binding to MHC class I. However,
the biological functions of PA28 are still relatively unknown. PA28
does not enhance rates of protein degradation by either the stan-
dard proteasome or the immunoproteasome. In fact, PA28-20S
particles degrade proteins at the same slow rate as 20S particles
alone (Raule et al., 2014a). PA28 appears to enhance the ability of
the 20S proteasome to degrade short peptide substrates, but not
proteins or polyubiquitinated proteins (Dubiel et al., 1992; Ma
et al., 1992). PA28 is also able to associate with asymmetric 26S
proteasomes (20S proteasomes with only one 19S regulatory com-
plex, usually denoted as 19S-20S) to form hybrid proteasomes
(19S-20S-PA28; Figure 3; Hendil et al., 1998; Tanahashi et al.,
2000; Kopp et al., 2001; Cascio et al., 2002). Hybrid proteasomes
hydrolyze 3- and 4-residue peptides at faster rates than standard
26S particles.
An extensive study of the molecular mechanisms of PA28 was
recently undertaken by Raule et al. (2014a) who performed in vitro
degradation of full-length proteins (insulin-like growth factor-1
and casein) by 20S, 26S, and PA28α/β-20S immunoproteasomes
and analyzed the range of peptides released. Rather than increase
the fraction of 8–10 residue peptides that is generated, associa-
tion of PA28 with 20S immunoproteasomes reduces it from 10%
to approximately 6% of the total, with the majority of peptides
being <6 amino acids in length. This may occur through allosteric
modiﬁcation of proteasome active sites by PA28α/β. Alternatively,
PA28α/βmay control the efﬂux of longer peptides out of the prote-
olytic chamber and contribute to their ongoing hydrolysis (Raule
et al., 2014a; Yang and Schmidt, 2014).
Binding of PA28 to the 20S catalytic core also appears to
favor the release of a speciﬁc subset of longer peptides with
an acidic C terminus, several of which contain the correct C-
terminal anchor residue required for binding to MHC class I
(Raule et al., 2014a). Several studies have demonstrated that PA28
expression enhances MHC class I presentation of certain anti-
gens (Groettrup et al., 1996b; Schwarz et al., 2000; van Hall et al.,
2000; Sun et al., 2002) but not others (Murata et al., 2001). It
was proposed that this small fraction of peptides speciﬁcally
generated by PA28-20S immunoproteasomes may be important
in stimulating an effective CD8 T cell response under certain
pathophysiological conditions in which a ubiquitin-independent
proteolytic pathway is favored. However, since the vast major-
ity of peptides released by PA28-20S immunoproteasomes are
too short to serve as MHC class I antigens, an alternative pos-
sibility is that PA28 may play a regulatory role by preventing
excessive cytotoxic response against self-antigens, and decrease
the risk of autoimmune reactions. A recent study demonstrated
that puriﬁed PA28α/β increases the capacity of both the constitu-
tive 20S proteasome and the immunoproteasome to selectively
degrade oxidized proteins in response to hydrogen peroxide-
induced oxidative stress, supporting a role for PA28 that is
independent of MHC class I antigen processing (Pickering and
Davies, 2012).
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Although PA28 does not stimulate proteolytic degradation
under normal conditions, PA28 does increase catalytic rates
of the immunoproteasome under conditions of ATP depletion
(Freudenburg et al., 2013b). The implications of PA28 regula-
tion by cellular ATP levels are unknown. Proinﬂammatory
cytokines, such as IL-1 and IFNs, signiﬁcantly decrease total
cellular ATP levels (Corbett et al., 1992; Collier et al., 2006). It
is possible that decreases in ATP levels that could occur during
inﬂammatory conditions such as viral infection trigger increased
association of PA28 with 20S immunoproteasomes and enhance
rates of protein degradation. However, given that the majority
of peptides degraded by PA28-20S proteasomes and immuno-
proteasomes are not suitable for binding to MHC class I, it
seems unlikely that this added level of regulation is related
to MHC class I antigen processing. It may instead be related
to possible roles for PA28 in degradation of oxidized proteins
or decreasing the potential for autoimmune reactions at sites
of inﬂammation, as discussed above. If PA28 does dampen
autoimmunity, then one would expect to see an increase in
autoimmune responses in PA28-deﬁcient mice after an inﬂamma-
tory response. These are intriguing possibilities that bear further
investigation.
STRATEGIES TO STUDY IMMUNOPROTEASOME FUNCTION
Until recently, traditional gene deletion has been the main strat-
egy employed to study immunoproteasome function. There are
numerous drawbacks to this approach. Due to cooperative assem-
bly of immunoproteasomes, deﬁciency in one subunit could
affect the structure and assembly of the 20S core, as well as
impair binding or activity of regulatory subunits. Mice deﬁ-
cient in one or more of the immunosubunits since birth could
develop compensatory mechanisms of proteasome or immuno-
proteasome assembly, leading to alteration in subunit composition
that could detrimentally affect peptide processing. They could
also have defects in maturation of the immune system, since the
thymoproteasome (composed of β1i, β2i, and the cTEC-speciﬁc
subunit β5t) is important for positive selection of T cells (Murata
et al., 2007). Most studies of immunoproteasome function have
been undertaken with mice in which only one or two immuno-
subunits are deleted, rather than all three. It is possible that a
standard proteasome subunit is able to compensate when only
one or two immunosubunits are missing, in which case a phe-
notype would not be observed unless the mice are lacking all
immunoproteasome activity. Therefore, caution must be taken
in drawing conclusions from studies using mice deﬁcient in one
or more immunosubunits.
Small molecule peptide screens have led to the identiﬁcation of
inhibitors speciﬁc to immunoproteasome activity. The use of small
molecule inhibitors offers several advantages over traditional gene
deletion approaches, the most obvious of which is their poten-
tial for use as therapeutics. Because small molecule inhibitors are
unlikely to affect the assembly or structure of the immunopro-
teasome, they allow for the study of how the catalytic activity of
a speciﬁc subunit affects immune responses. Furthermore, these
inhibitors are unlikely to affect the positive selection of T cells in
the thymus, since most studies are undertaken in adult mice after
maturation of the immune system.
The ﬁrst reported immunoproteasome-speciﬁc inhibitor,
PR-957 (now known as ONX 0914), inhibits β5i with an IC50
value of approximately 10 nM (Muchamuel et al., 2009). ONX
0914 is 20- to 40-fold more selective for β5i than for the next
two most sensitive subunits, β1i and β5. A newer β5i-speciﬁc
inhibitor, PR-924, speciﬁcally targets β5i and has less speciﬁcity
toward other subunits compared to ONX 0914 (Parlati et al.,
2009). UK-101 was the ﬁrst identiﬁed compound to speciﬁ-
cally inhibit β1i (Ho et al., 2007; Wehenkel et al., 2012), with
two more (IPSI-001 and YU-102) identiﬁed shortly thereafter
(Kuhn et al., 2009; Miller et al., 2013). Leupeptin is a recently
described inhibitor of the trypsin-like activity of the protea-
some (β2 and β2i) that does not affect activity of other β
subunits (Kisselev et al., 2006; Raule et al., 2014b). There are
currently no available compounds that speciﬁcally inhibit the
activity of β2i. A recent crystal structure of the murine con-
stitutive proteasome and the immunoproteasome in complex
with ONX 0914 revealed important structural differences in the
binding pockets of the different subunits (Huber et al., 2012).
While the crystal structures demonstrated that β1 and β5 have
distinct substrate binding pockets that are distinct from those
of their immunosubunit counterparts, the substrate binding
pockets of β2 and β2i are essentially identical. Therefore, it
will be difﬁcult to develop β2i inhibitors that do not also tar-
get its constitutive counterpart. Several other proteasome- and
immunoproteasome- speciﬁc inhibitors are in development and
are of signiﬁcant interest as potential therapeutic agents (Miller
et al., 2013).
IMMUNOPROTEASOME AND ACTIVATION OF THE NF-κB
PATHWAY
The nuclear factor-κB (NF-κB/Rel) family of transcription factors
plays a central role in regulation of immunity and inﬂamma-
tion. NF-κB transcription factors interact as homodimers or
heterodimers with other NF-κB family members, including p65
(RelA), RelB, c-Rel, p50 (NF-κB1), and p52 (NF-κB2). Under
normal conditions, these factors exist in the cytoplasm in an
inactive state because of interaction with inhibitory IκB proteins
(IκBα, IκBβ, IκBε) or the unprocessed forms of NF-κB1 and
NF-κB2 (p105 and p100, respectively). The NF-κB pathway is
activated in response to many different stimuli, including expo-
sure to inﬂammatory cytokines such as TNF-α or IL-1 family
members (Vallabhapurapu and Karin, 2009). In the canoni-
cal or classical pathway of NF-κB activation, the proteasome
degrades IκBα, releasing the activeNF-κBdimer (usually p65/p50)
and allowing translocation to the nucleus. In the non-canonical
or alternative pathway of NF-κB activation, the proteasome
degrades the inhibitory portion of p105 or p100 to generate
the active transcription factors p50 or p52. These transcrip-
tion factors can then associate with p65, RelB, or each other to
form homodimers and heterodimers. The classical and alterna-
tive NF-κB pathways regulate distinct sets of target genes, in part
because different populations of NF-κB dimers are regulated by
either IκBα degradation or p100 processing (Hayden and Ghosh,
2008).
It is widely accepted that the standard proteasome plays a
crucial role in the processing of the p105 precursor of the p50
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subunit and in the degradation of IκBα (Palombella et al., 1994;
Traenckner et al., 1994). However, a role for the immunoprotea-
some in NF-κB pathway activation is controversial. Non-obese
diabetic (NOD) mice were reported to have a speciﬁc defect in
β1i production that resulted in defective activation of NF-κB
(Hayashi and Faustman, 1999). This ﬁnding has been debated,
but contradictory results were likely due to different cell pop-
ulations and the phenotype (non-diseased versus diseased) of
NOD mice analyzed (Hayashi and Faustman, 1999; Kessler et al.,
2000; Runnels et al., 2000). Nevertheless, Hayashi and Faust-
man (1999) did directly demonstrate impaired NF-κB activation
in lymphocytes from β1i−/− mice. The T2 human lymphocyte
cell line, which lacks both β1i and β5i, has substantial defects
in NF-κB activation compared to the parental T1 cell line and
is sensitive to TNF-α-induced apoptosis (Hayashi and Faustman,
2000).
In support of a role for the immunoproteasome in NF-κB acti-
vation, another study reported delayed termination of the classical
NF-κB activation pathway and reduced activation of transcription
factors associated with the alternative NF-κB pathway in β1i−/−
mice, but not β1i/β5i double knockout mice (Maldonado et al.,
2013). B cells isolated from β1i−/− mice exhibit slightly delayed
IκB degradation, although the authors posited that defects in these
micewere likely due to thepresence of mixedproteasomes contain-
ing β1, β2i, and β5i because a B cell phenotype was not observed in
mice lacking both β1i and β2i (Hensley et al., 2010). It is important
to note that the mixed proteasomes may have abnormal function
that is directly responsible for observed defects in NF-κB activa-
tion in β1i−/− mice (discussed in more detail below). If that is the
case, then the deﬁciencies in these cell types in β1i−/− mice are
not a true reﬂection of deﬁcient immunoproteasome function.
In support of this possibility, another study used two small
molecule inhibitors of the immunoproteasome, UK-101 and
LKS01, which target β1i and β5i, respectively, to study the role of
the immunoproteasome in NF-κB activation in lung and pancre-
atic adenocarcinoma cells (Jang et al., 2012). Their results suggest
that the catalytic activity of β1i and β5i is not required for canon-
ical NF-κB activation (as measured by IκB degradation), and they
support the notion that deﬁciencies inNF-κB activation in β1i−/−
mice may instead be an artifact of mixed proteasomes. One study
demonstrated reduced NF-κB activation in cardiomyocytes and
B-cell-depleted splenocytes in β5i−/− mice following exposure to
IFN-γ (Opitz et al., 2011). However, because NF-κB activation
in this study was measured by assessing p50 levels in whole cell
homogenates, it is unknown whether the reduced levels in β5i−/−
mice were due to impaired activation of the classical or alternative
NF-κB pathway.
Since some studies have reported impaired activation of the
alternative NF-κB pathway in β1i−/− mice, it will be important
to repeat the UK-101 and LKS01 inhibitor studies to determine
whether the catalytic activity of β1i or β5i is important in the alter-
native pathway of NF-κB activation by measuring p100 or p105
degradation. Additionally, it remains to be determined whether
other cell types, such as those of the immune system that express
the immunoproteasome constitutively, use immunoproteasome
activity in the either the classical or alternative pathway of NF-κB
activation.
IMMUNOPROTEASOME FUNCTIONS IN ANTIGEN
PROCESSING AND VIRAL INFECTION
Immunoproteasome function appears to be important for a vari-
ety of host responses to viral infection, although the speciﬁc effects
depend on the virus studied and the models used (summarized in
Table 1). Because β1i and β5i are encoded on the MHC locus, it
was originally thought that the major function of the immuno-
proteasome is to regulate the immune response via optimization
of MHC class I peptide processing. Although proteasome activity
in general is required for MHC class I antigen presentation, the
immunoproteasome does not appear to be essential for that func-
tion. In fact, some epitopes are processed more efﬁciently by the
20S proteasome than the immunoproteasome [(Morel et al., 2000;
Van den Eynde and Morel, 2001) and discussed above]. How-
ever, the immunoproteasome is certainly more effective than the
standard proteasome at producing many MHC class I epitopes,
particularly immunodominant epitopes derived from infectious
organisms. Many of the epitopes processed inefﬁciently by the
immunoproteasome are derived from self proteins (VandenEynde
and Morel, 2001). While these epitopes may be important for gen-
erating an immune response to tumor antigens and could have
implications for design of cancer vaccines, it is unlikely that they
play a role in the immune response to an infectious organism.
The immunoproteasome appears to facilitate T cell responses
that are independent of MHC class I antigen presentation. A com-
mon phenotype of immunoproteasome-deﬁcient mice is reduced
number of CD8 T cells in the spleen, supporting contributions of
the immunoproteasome to T cell development ormaturation (Van
Kaer et al., 1994; Hensley et al., 2010; Basler et al., 2011). A number
of studies have reported increased CD4/CD8 T cell ratios β2i−/−
mice (Chen et al., 2001; Caudill et al., 2006; Basler et al., 2013a),
and this has recently been ascribed to a T-cell-intrinsic process
that occurs independently of both thymic selection and antigen
processing (Zaiss et al., 2008). T cells from β1i−/−, β2i−/−, or
β5i−/− mice are impaired in proliferation and survival when
transferred into virus-infected wild-type mice, suggesting a role
for the immunoproteasome in the expansion and maintenance of
T cell populations during an immune response (Chen et al., 2001;
Basler et al., 2006; Moebius et al., 2010).
The immunoproteasome may also play a critical role in B cell
development, as mice deﬁcient in β1i, but not β1i/β2i or β5i/β2i,
have reduced numbers of mature B cells in the spleen (Hensley
et al., 2010). These authors reported reduced survival and impaired
immunoglobulin (Ig) isotype switching in B cells from β1i−/−
mice compared to wild-type B cells. A separate report was unable
to recapitulate the ﬁnding of reduced B cells in β1i−/− mice, and it
demonstrated equivalent numbers of CD19+ B cells in the spleens
of mice deﬁcient in β1i, β2i, or both β1i/β2i (Basler et al., 2011).
B cell responses were not examined in detail in that study. There-
fore, the role of the immunoproteasome in B cell development or
induction of a humoral response following a viral infection is still
largely undeﬁned.
The immunoproteasome, or at least theβ5i subunit, plays a crit-
ical role in generating nearly allmouse cytomegalovirus (MCMV)-
derived epitopes (Hutchinson et al., 2011). Interestingly, memory
“inﬂating” epitopes, or epitopes for which the pool of speciﬁc
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Table 1 | Contributions of immunoproteasome function during viral infection.
Virus Immunoproteasome
inhibition/deficiency
Effects on CD8T cell function Other effects on immune response and inflammation
MCMV β5i−/− • Nearly all MCMV-speciﬁc epitopes decreased
• Memory-inﬂating epitopes less dependent on
the immunoproteasome
HBV β1i−/−β5i−/− • Moderately reduced CD8T cell responses to
HBV polymerase and envelope proteins
Inﬂuenza β1i−/− • Reduced capacity of APCs to generate
inﬂuenza NP epitope
• Decreased responses to immunodominant
epitopes
• Reduction in overall number of inﬂuenza
virus-speciﬁc CD8T cells
• B cells display survival defect and reduced isotype
switching
• DCs show reduced innate cytokine production
• Inﬂuenza virus titers in sera reduced
LCMV β2i−/− • Reduced response to some LCMV-derived
epitopes
β1i−/−β2i−/− plus
ONX 0914
• Largely normal CD8T cell responses
β5i−/− • Delayed and less robust CNS inﬂammation
β1i−/−β2i−/−β5i−/− • Signiﬁcantly decreased CD8T cell responses • MHC class II presentation and CD4T cell responses
unchanged
CVB3 β5i−/− • No effect on CD8T cell responses in the heart • No effect on CVB3 replication
• Increased severity of myocardial tissue damage
• Increased polyUb conjugates and oxidant-damaged
proteins in the heart
• Increased apoptosis in the heart
CD8 T cells is sustained or even increased over time, show a
reduced dependence on the immunoproteasome compared to
non-inﬂating epitopes. This suggests that immunoproteasomes
play a role in stimulating immune responses during acute infec-
tion, but not during chronicMCMVinfection. Although this study
did not monitor the effect of β5i deﬁciency on MCMV viral loads
over time, it was suggested that β5i deﬁciency likelywould not have
an impact on MCMV replication because neither CD8 nor MHC
class I deﬁciency have an impact on viral loads in this model.
The immunoproteasome (subunits β1i and β5i) moderately
inﬂuences themagnitude and speciﬁcity of CD8T cell responses to
hepatitis B virus (HBV) polymerase and envelope proteins (Robek
et al., 2007). Although type I IFNs and IFN-γ inhibit HBV repli-
cation, the antiviral effect of IFNs occurs independently of their
induction of β1i and β5i.
The majority of studies examining the effect of immunopro-
teasome deﬁciency on the generation of antigenic epitopes during
viral infection have been performedwith inﬂuenza virus or LCMV,
two well-studied viruses for which the immunodominant CD8 T
cell epitopes are known. The WE strain has been the most com-
monly used strain for LCMV-immunoproteasome studies, while
the Armstrong and clone 13 strains have been used far less fre-
quently. It is important to consider potential differences associated
with the use of different LCMV strains, which vary greatly in terms
of their interactions with host immune function and their ability
to persist in an infected host.
APCs from β1i−/− mice show a reduced capacity to generate an
inﬂuenza virus nucleoprotein-speciﬁc epitope, while presentation
of OVA-derived antigens was unaffected (Van Kaer et al., 1994).
Two later studies using seven deﬁned peptides from inﬂuenza
virus showed that β1i (and to a lesser extent the other immuno-
proteasome subunits) plays a major role in establishing the
immunodominance hierarchy of responding CD8 T cells (Chen
et al., 2001; Pang et al., 2006). Responses to the two most immun-
odominant epitopes signiﬁcantly decreased in β1i−/− mice. One
of these was due to decreased generation of the epitope by APCs,
while the other was due to reduced frequency of epitope-speciﬁc
T cells in the CD8 T cell repertoire. The overall number of
inﬂuenza virus-speciﬁc CD8 T cells was decreased in β1i−/−
mice, even when β1i−/− CD8 T cells were restimulated with
APCS (inﬂuenza virus-infected splenocytes) from wild-type mice.
Because this defect was observed for epitopes produced equally by
standard proteasomes and immunoproteasomes, it was suggested
that immunoproteasomesmight play a role in T cell activation and
proliferation.
Interestingly, inﬂuenza virus titers are reduced approximately
50% in sera of β1i−/− mice. While B cells from inﬂuenza virus-
infected β1i−/− mice proliferate as well as those from wild-type
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mice, they display a survival defect and impaired Ig isotype switch-
ing. DCs from the same mice show reduced innate cytokine
production in response to inﬂuenza virus infection (Hensley et al.,
2010). The altered response of many cell types in β1i−/− mice to
inﬂuenza virus is likely due to the presence of mixed proteasomes
containing β2i and β5i.
Care must be taken in the interpretation of results obtained
using β1i−/− mice, since results cannot be attributed solely
to absence of β1i catalytic activity. Instead, any effect may be
due to dysregulated proteasome assembly and function. While
mixed proteasomes containing both standard and immunosub-
units have recently been isolated from wild-type mice, these
mixed proteasomes contain either β1i/β5i or just β5i, in accor-
dance with the rules of cooperative immunoproteasome assembly
(Guillaume et al., 2010). The authors of that study were unable
to detect the presence of mixed proteasomes containing β2i, as
all of the β2i subunits were associated with immunoproteasomes.
Cooperative assembly rules should preclude formation of mixed
proteasomes containing β2i, because both β1i and β5i are required
for its inclusion in the immunoproteasome. It is possible that β5i
could compensate (perhaps partially or inefﬁciently) for β1i in
the assembly process, or that β2i could interact with the stan-
dard β1 subunit in the complete absence of β1i (as in β1i−/−
mice). This may explain the seemingly contradictory presence
of mixed β2i/β5i proteasomes in β1i−/− mice. It is doubtful
that mixed proteasomes containing β2i exist in wild-type mice,
although this has not been formally analyzed in all tissues or cell
types. Mixed proteasomes (containing β1i/β5i or β5i alone) are
highly expressed in human immature and mature DCs. Human
monocytes also contain a particularly high abundance of mixed
proteasomes, up to 50% of the total proteasome content. The
mixed proteasome content of B and T cells is unknown. How-
ever, the ﬁnding that mixed proteasomes are expressed at high
levels in some cell types, particularly APCs, suggests that they may
play an important role in shaping CD8 T cell responses. Indeed,
work by Zanker et al. (2013) using mice deﬁcient in β1i, β2i,
or β2i/β5i demonstrated that mixed proteasomes increase viral
peptide diversity and broaden antiviral CD8 T cell responses to
inﬂuenza virus.
Mice deﬁcient in β2i have ∼20% fewer CD8 T cells in the
spleen and reduced response to some LCMV-derived epitopes
(WE strain). This is not due to impaired generation or presen-
tation of these epitopes, but rather to either decreased precursor
frequency or reduced expansion of the epitope-speciﬁc T cells,
further supporting a role for the immunoproteasome in T cell
survival or expansion rather than just antigen presentation (Basler
et al., 2006). One strategy that has been employed to study mice
lacking all immunoproteasome activity has been to use β1i/β2i
double knockout mice treated with the β5i-speciﬁc inhibitor
ONX 0914 (Basler et al., 2011). Although these mice have fewer
CD8 T cells in the spleen, and CD8 T cell responses to sev-
eral LCMV-speciﬁc MHC class I epitopes are changed (two are
increased and others are decreased; again WE strain), these dou-
ble knockout mice otherwise mount largely normal CD8 T cell
responses to LCMV infection. Spleen LCMV titers at 4 dpi were
unchanged in immunoproteasome-deﬁcient mice treated with
ONX 0914, although it remains to be seen whether viral titers
at later times (such as at 8 dpi, when CD8 T cell responses were
analyzed) would be affected by lack of immunoproteasome activ-
ity. Splenocytes isolated from β1i−/−β2i−/− ONX 0914-treated
mice and stimulated with LPS or α-CD3/CD28 had reduced pro-
duction of IL-6, TNF-α, and IFN-γ. However, this defect was
observed in stimulated splenocytes from wild-type mice treated
with ONX 0914 alone, suggesting a specialized function of β5i in
promoting cytokine production that is not shared by the other
immunosubunits. Because the cytokine studies in mice lacking
immunoproteasome activity were performed in splenocytes stim-
ulated ex vivo or in other models, it is unknown whether these
mice display defects in cytokine production in response to LCMV
or other viruses in vivo. The relatively modest effect of impaired
immunoproteasome activity on the generation of LCMV-speciﬁc
IFN-γ+ CD8 T cells suggests that overall IFN-γ production may
be unaffected. However, β1i−/−β2i−/− ONX 0914-treated mice
may still have defects in production of other cytokines, such as
IL-6 or TNF-α, in response to LCMV or other viruses.
Immunoproteasome subunits are transcriptionally induced in
the brain following LCMV (WE strain) infection (Kremer et al.,
2010). Mature immunoproteasome assembly is almost exclusively
restricted to microglial-like cells, while only immunoproteasome
precursors exist in astrocytes and do not exist at all in neu-
rons or oligodendrocytes. LCMV-induced meningitis is delayed
and less severe in β5i−/− mice, suggesting a role for microglial
immunoproteasomes in exacerbating immunopathology. The lack
of mature immunoproteasome assembly in astrocytes may be due
to a posttranslational mechanism that prevents excess immuno-
proteasomeassembly in thebrain. Since cells in theCNS regenerate
poorly or not at all, inhibition of immunoproteasome assembly
might be a strategy to protect these cells from immunopathological
destruction.
The above studies demonstrate subtle and possible organ- or
virus-speciﬁc roles for the immunoproteasome during viral infec-
tion using mice deﬁcient in only one or two immunosubunits.
To assess the role of complete immunoproteasome deﬁciency, a
recent study generated mice deﬁcient in all three immunoprotea-
some subunits (triply deﬁcient mice; Kincaid et al., 2012). This
had not been performed previously because the LMP2 and LMP7
genes (encoding β1i and β5i, respectively) are closely linked on the
same chromosome and ﬂank the TAP1 transporter gene, so that
breedingβ1i−/− andβ5i−/− micewith eachotherwouldnot likely
result in a double knockout but leave TAP1 unaffected. However,
Kincaid et al. (2012) used a sequential deletion strategy to ﬁrst
generate β1i/β5i doubly deﬁcient mice, which were then bred to
β2i−/− mice to generate the triply deﬁcientmice. APCs from these
mice display profounddefects inMHCclass I antigenpresentation,
defects that are much more severe than those previously described
in β1i, β2i, or β5i single knockoutmice. These ﬁndings suggest that
there may be functional overlap between the immunosubunits,
and that the crucial role of immunoproteasomes in MHC class I
antigen presentation has been obscured or underestimated by the
use of mice deﬁcient in only one immunosubunit. Triply deﬁcient
mice have an approximately 50% reduction in surface levels of
MHC class I (Kincaid et al., 2012). This is likely due to a reduction
in the supply of peptides available to bind toMHCclass Imolecules
within the cell, rather than a defect in MHC class I expression
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itself. Of note, a similar 50% reduction of MHC class I surface
expression is also observed in β5i−/− mice, but not mice lacking
either β1i or β2i, probably because β5i−/− mice have amore severe
defect in immunoproteasome assembly than β1i−/− or β2i−/−
mice (Fehling et al., 1994). Presentation of nearly all MHC class
I epitopes examined is signiﬁcantly decreased in immunosubunit
triply deﬁcient mice both in vitro and in vivo. During LCMV infec-
tion (Armstrong strain), triply deﬁcient mice display substantially
weaker CD8 T cell responses than wild-type mice. This is due
to defects in antigen presentation (and not to pleiotropic effects
on T cells), because weaker T cell responses are also observed in
wild-type T cells transferred into triply deﬁcient mice. MHC class
II epitope presentation and CD4+ T cell responses to LCMV are
similar in wild-type and triply deﬁcient mice, suggesting that the
immunoproteasome does not affect processing of MHC class II
antigens. It remains to be seen whether complete immunopro-
teasome deﬁciency (and the resulting substantially weaker CD8
T cell response) affects LCMV replication or other virus-induced
inﬂammatory responses, such as cytokine production.
In addition to defects in antigen presentation, mice deﬁ-
cient in one or multiple immunoproteasome subunits have
a peptide repertoire that substantially differs from wild-type
mice, leading to rejection of wild-type cells when intro-
duced into immunoproteasome-deﬁcient mice (Toes et al., 2001;
de Verteuil et al., 2010; Kincaid et al., 2012). The ﬁnding that
standard proteasomes and immunoproteasomes generate such
vastly different peptide repertoires has important implications.
Under non-inﬂammatory conditions, the peptides presented on
DCs (which constitutively express both standard proteasomes
and immunoproteasomes) will be signiﬁcantly different from the
peptides displayed on non-immune parenchymal cells (which
express only standard proteasomes). This implies that CD8 T
cells stimulated by DCs may not efﬁciently recognize peptides
displayed by non-immune cells until immunoproteasomes are
induced in those non-immune cells by IFN. In cells that do not
respond to IFN-γ and/or do not express immunoproteasomes,
such as cells infected with a virus that inhibits IFN-γ signal-
ing, this could suppress CD8 T cell responses and contribute
to immune evasion. The differences in peptide repertoires pro-
duced by standard proteasomes and immunoproteasomes also
have implications for acute inﬂammatory responses and vaccine
design. During LCMV (WE strain) or Listeria monocytogenes
infection, standard proteasomes in the liver are almost com-
pletely replaced by immunoproteasomes within the ﬁrst 7 days
of infection, leading to strongly altered proteasome activity
(Khan et al., 2001). This suggests that CD8 T cell responses
during the acute phase of viral and bacterial infection are pri-
marily directed at immunoproteasome-dependent epitopes. Vac-
cines directed against epitopes that are poorly processed by the
immunoproteasome would likely exhibit a less robust CD8 T cell
response and not generate optimal protection against a particular
pathogen.
Interestingly, immunoproteasomes assemble approximately
four times faster than, and show greatly reduced stability rela-
tive to standard proteasomes (Heink et al., 2005). This suggests
that immunoproteasome induction is a tightly regulated process,
in which cytokines induced during the ﬁrst few days of a viral
infection signal a pressing need for immunoproteasome activity
in the infected tissue. The relative instability of immunoprotea-
somes would provide a means for infected cells and tissues to
quickly return to a normal state once immunoproteasomes are
no longer needed, and it may suggest that ongoing or long-term
immunoproteasome expression could actually be detrimental.
The role of the immunoproteasome during viral infection is
still largely undeﬁned, and there is evidence for organ-, virus-, and
mouse strain-speciﬁc effects. Further studies are needed, especially
with the newly generated triply deﬁcient mice in which immuno-
proteasome activity is completely absent. Most studies examining
immunoproteasome function during viral infection have focused
almost exclusively on the effect of immunoproteasome subunits
in shaping the repertoire of peptides available for MHC class I
processing, and thus the hierarchy of CD8 T cell responses. How-
ever, the main function of the immunoproteasome during viral
infection may actually be independent of the MHC class I anti-
gen processing pathway. This is supported by the fact that B and
T cells, which do not generally have a signiﬁcant role as antigen-
presenting cells (via MHC class I), express immunoproteasomes.
A number of studies have suggested major roles for the immuno-
proteasome in T cell proliferation and survival, and there are hints
from β1i−/− mice that the immunoproteasome is also important
for B cell development, as described above.
Accumulating evidence suggests that the immunoproteasome
is critical for the removal of oxidized proteins and adaptation to
oxidative stress (Ferrington et al., 2005, 2008; Kotamraju et al.,
2006; Ethen et al., 2007; Hussong et al., 2010; Pickering et al.,
2010). During coxsackievirus B3 (CVB3)-induced myocarditis,
β5i−/− mice developed more severe myocardial tissue damage
compared to wild-type mice (Opitz et al., 2011). This was not
due to a direct effect on viral replication. It is interesting to
note that CD8 T cell responses in the heart, as measured by
ﬂow cytometry and immunohistochemistry, were equivalent or
even slightly enhanced in β5i−/− mice after CVB3 infection,
suggesting that severe tissue damage in β5i−/− mice was not
due to an alteration in the CD8 T cell response. Rather, car-
diomyocytes and inﬂammatory cells from β5i−/− mice showed
increased accumulation of polyubiquitinated protein conjugates
and oxidant-damaged proteins following treatment with IFN-γ.
Hearts from CVB3-infected β5i−/− showed signiﬁcant apoptotic
cell death compared to infected wild-type mice. These ﬁnd-
ings suggest that the immunoproteasome protects cells from
cytokine-induced proteotoxic stress by removing polyubiquiti-
nated or oxidant-damaged proteins. Whether this role for the
immunoproteasome is unique to CVB3-induced myocarditis or
can be applied to other viral infections and disease states is
unknown.
A recent study has suggested a new role for immunoprotea-
somes in maintaining cellular homeostasis (Raule et al., 2014b).
Raule et al. (2014b) demonstrated that 26S immunoproteasomes
degrade basic proteins at four- to sixfold higher rates compared
to 26S standard proteasomes. This effect is observed speciﬁ-
cally for proteins with a basic isoelectric point (high content in
lysine and arginine residues), and not for neutral proteins. His-
tones, in particular, are extremely basic. Stimulation of cells with
proinﬂammatory cytokines induces transcription of hundreds of
Frontiers in Microbiology | Virology January 2015 | Volume 6 | Article 21 | 10
McCarthy andWeinberg Immunoproteasome and viral infection
genes through multiple regulatory pathways (Boehm et al., 1997;
Schroder et al., 2004). Accumulation of free histones released
from these sites of transcription could result in genomic insta-
bility and transcriptional inhibition (Singh et al., 2009). The
ability of immunoproteasomes to remove excess free histones
more efﬁciently than standard proteasomes could be an impor-
tant mechanism by which immunoproteasomes maintain cellular
homeostasis under conditions of stress and inﬂammation. This
also suggests an additional reason for why CVB3-infected β5i−/−
mice have increased cellular damage and apoptotic cell death
in heart tissue compared to wild-type mice. Perhaps β5i−/−
mice are unable to cope with the combined accumulation of
oxidant-damage proteins and excess free histones in response to
cytokine-induced stress and transcriptional activation.
Few studies have examined the effect of immunoproteasome
deﬁciency on inﬂammation and protection of cells from virus-
or cytokine-induced death during viral infection. It would be
interesting to extend the studies described above with inﬂuenza,
MCMV, LCMV, or other viruses in order to assess the role of
the immunoproteasome in other aspects of the inﬂammatory
response besides the generation of virus-speciﬁc epitopes for CD8
T cell responses.
PATHOGEN INTERACTION WITH THE IMMUNOPROTEASOME
Components of many pathogens have been shown to interact with
the immunoproteasome pathway. Perhaps not surprisingly, many
of these pathogens establish chronic or persistent infections. Inter-
ference with the immunoproteasome pathway may be a common
mechanismbywhich these pathogens inhibit CD8T cell responses,
either during acute infection (to facilitate the establishment of per-
sistence) or during long-term persistence for ongoing evasion of
the immune system.
HIV-1 inhibits immunoproteasome function, likely by a num-
ber of mechanisms (Haorah et al., 2004). Expression of viral p24
downregulates PA28β, β2i, and β5i in a DC line (JAWS II) and
primary DCs. Exposure of those cell lines to HIV-1 p24 leads
to a decrease in antigen presentation that can be overcome by
pretreatment of cells with IFN-γ (such that the immunoprotea-
some is already upregulated by the time of p24 addition; Steers
et al., 2009). HIV-1 Tat protein interacts with six β subunits
of the standard 20S proteasome, as well as the immunosub-
units β2i and β5i, to decrease catalytic activity (Apcher et al.,
2003). Tat also binds to two α subunits, α4 and α7, prevent-
ing interaction of PA28 with the 20S core (Huang et al., 2002).
The hepatitis C virus (HCV) non-structural protein NS3 directly
binds to β5i and reduces immunoproteasome activity (Khu et al.,
2004). Downregulation of immunoproteasome protease activity
has been suggested as a mechanism by which HCV could inter-
fere with processing of viral antigens for presentation on MHC
class I and could avoid host immune surveillance during persistent
infection.
Human adenovirus E1A interacts with the immunoprotea-
some subunit β2i, but not its constitutive counterpart β2. E1A
(either in the context of adenovirus infection or via overexpression
of E1A in the absence of other viral genes) also prevents IFN-
γ-induced upregulation of immunoproteasome subunit expres-
sion by interfering with STAT1 phosphorylation (Berhane et al.,
2011). Of note, adenoviruses have developed many other pre-
and post-translational strategies to interfere with MHC class I
processing and presentation that are independent of direct inter-
actions between viral proteins and immunoproteasome subunits
(reviewed in Blair and Blair-Zajdel, 2004).
Both human cytomegalovirus (HCMV) and MCMV inhibit
IFN-γ-induced immunoproteasome formation in ﬁbroblasts in
vitro (Khan et al., 2004). Inhibition of immunoproteasome for-
mationoccurs at a pretranscriptional level, because transcriptional
upregulation of PA28α/β, as well as all three immunosubunits, is
impaired by infection. When cells are infected with an MCMV
virus lacking M27, a gene that encodes a STAT2 inhibitor that
interferes with IFN-γ receptor signaling, immunoproteasome
expression is no longer inhibited.
CONCLUSION
CD8 T cells often play signiﬁcant roles during viral infection. In
endogenous antigen presentation, the proteasome is crucial for
the generation of antigenic peptides for binding to MHC class I
and promoting CD8 T cell responses. The immunoproteasome
is a specialized type of proteasome with altered peptide cleavage
properties that is constitutively expressed in hematopoietic cells
and induced in non-immune cells under conditions of inﬂamma-
tion. Evidence suggests that the immunoproteasome may play an
important role during viral infection through regulation of CD8 T
cell responses, activation of the NF-κB pathway, and management
of oxidative stress. Many viruses have mechanisms of interfering
with MHC class I processing, including direct interaction of viral
proteins with immunoproteasome subunits. It is essential to bet-
ter understand the role of the immunoproteasome in different
cell types, tissues, and hosts in the context of diverse inﬂamma-
tory states. An improved understanding of the mechanisms of
immunoproteasome function could aid in the development of
vaccines and treatment strategies for viral infections.
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